Concizumab is a tissue factor pathway inhibitor antagonist that enhances factor Xa production during the initiation phase of coagulation. This production improves thrombin generation and clot ...

The Food and Drug Administration (FDA) has approved Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

CBD did not meet primary end point comparing preingestion to postingestion anxiety, but resulted in lower anxiety levels ...

(HealthDay News) — Light-to-moderate consumption of wine, measured through an objective urinary biomarker, is associated with lower cardiovascular disease (CVD) risk in an older Mediterranean ...

Results from the VENTURE trial showed significant reductions in weight and hunger among younger patients treated with ...

(HealthDay News) — The use of influenza testing at hospital emergency department visits increased from 2013 to 2022 in the United States, according to a December data brief published by the National ...

Veligrotug is an investigational monoclonal antibody that inhibits the activity of insulin-like growth factor-1 receptor.

The FDA is recommending an additional clinical trial to confirm glepaglutide’s efficacy and safety at the to-be-marketed dose.

The Food and Drug Administration (FDA) has approved Tryngolza™ (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

The investigational therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor.

The BLA acceptance was supported by data from the randomized, placebo-controlled phase 2b/3 CLEVER trial as well as interim ...

The approval was based on data from 2 randomized, double-blind, placebo-controlled trials, ARCADIA 1 and ARCADIA 2.